Viet Nam
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 92 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 17 (12–24) 19 (13–26)
Mortality (HIV+TB only) 2 (1.2–2.9) 2.1 (1.3–3.2)
Prevalence  (includes HIV+TB) 190 (79–350) 209 (86–384)
Incidence  (includes HIV+TB) 130 (110–160) 144 (121–174)
Incidence (HIV+TB only) 9.4 (8–12) 10 (8.7–13)
Case detection, all forms (%) 76 (63–91)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4 (2.5–5.4) 23 (17–30)
MDR-TB cases among notified pulmonary
TB cases
3 000 (1 900–4 100) 2 100 (1 500–2 600)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 50 607   7 059
Pulmonary, clinically diagnosed 24 403    
Extrapulmonary 18 326    
       
Total new and relapse 100 395    
Previously treated, excluding relapses 1 801    
Total cases notified 102 196    
Among 50 607 new cases:
143 (<1%) cases aged under 15 years; male:female ratio: 2.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 353 (<1%) 3 955 (45%) 4 531
Laboratory-confirmed RR-/MDR-TB cases     1 204
Patients started on MDR-TB treatment     948
TB/HIV 2013 Number (%)
TB patients with known HIV status 71 374 (70)
HIV-positive TB patients 4 438 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 205 (72)
HIV-positive TB patients on antiretroviral therapy (ART) 2 715 (61)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 91
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 72
RR-/MDR-TB cases started on second-line treatment in 2011 72
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 1.3
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 27
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 73
% Funded domestically 9%
% Funded internationally 18%
% Unfunded 73%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-23 Data: www.who.int/tb/data